Treatment guidelines in inflammatory bowel disease: The japanese perspectives

Digestive Diseases

Volumn 31, Issue 3-4, 2013, Pages 363-367

  Matsuoka, Katsuyoshi ^a   Hibi, Toshifumi ^b  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KITASATO UNIVERSITY   (Japan)

Author keywords

Crohn's disease; Guidelines; Ulcerative colitis

Indexed keywords

AZATHIOPRINE; BUDESONIDE; CORTICOSTEROID; CYCLOSPORIN; ENEMA; GASTROINTESTINAL AGENT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; PREDNISOLONE; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; AMINOSALICYLIC ACID; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

CLINICAL INDICATOR; COLON SURGERY; COMPARATIVE EFFECTIVENESS; CONFERENCE PAPER; CONSENSUS; CORTICOSTEROID THERAPY; CROHN DISEASE; CYTAPHERESIS; DIET THERAPY; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; ELEMENTAL DIET; ENTERIC FEEDING; HUMAN; JAPANESE; LEUKAPHERESIS; MULTICENTER STUDY (TOPIC); OPTIMAL DRUG DOSE; PATIENT SAFETY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; TREATMENT OUTCOME; TREATMENT RESPONSE; ULCERATIVE COLITIS; DIET; INFLAMMATORY BOWEL DISEASES; JAPAN; APHERESIS; CLINICAL PRACTICE; CULTURAL ANTHROPOLOGY; ELEMENTARY DIET; INFLAMMATORY BOWEL DISEASE; JAPANESE (PEOPLE); LEUKOCYTE; PHYSICIAN;

AMINOSALICYLIC ACID; ANTIBODIES, MONOCLONAL; DIET; HUMANS; INFLAMMATORY BOWEL DISEASES; JAPAN; PRACTICE GUIDELINES AS TOPIC; TACROLIMUS;

EID: 84888238937     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000354696     Document Type: Conference Paper

References (9)

1. Guidelines for the management of ulcerative colitis in Japan. http://minds4.jcqhc.or.jp/minds/kaiyouseida/ucgl+201102.pdf.
2. Ueno F, Matsui T, Matsumoto T, et al: Evidence-based clinical practice guidelines for Crohn's disease, integrated with formal consensus of experts in Japan. J Gastroenterol 2013;48: 31-72.
3. Van Assche G, Dignass A, Panes J, et al: The second European evidence-based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. J Crohns Colitis 2010;4: 7-27.
4. Mowat C, Cole A, Windsor A, et al: Guidelines for the management of inflammatory bowel disease in adults. Gut 2011;60: 571-607.
5. Talley NJ, Abreu MT, Achkar JP, et al: An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroenterol 2011;106(suppl 1):S2-S25, quiz S26.
6. Rutgeerts P, Sandborn WJ, Feagan BG, et al: Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353: 2462-2476.
7. Ogata H, Kato J, Hirai F, et al: Double-blind, placebo-controlled trial of oral tacrolimus (FK506) in the management of hospitalized patients with steroid-refractory ulcerative colitis. Inflamm Bowel Dis 2012;18: 803-808.
8. Sawada K, Kusugami K, Suzuki Y, et al: Leukocytapheresis in ulcerative colitis: results of a multicenter double-blind prospective casecontrol study with sham apheresis as placebo treatment. Am J Gastroenterol 2005;100: 1362-1369.
9. Nishioka C, Aoyama N, Maekawa S, et al: Leukocytapheresis therapy for steroid-naive patients with active ulcerative colitis: its clinical efficacy and adverse effects compared with those of conventional steroid therapy. J Gastroenterol Hepatol 2005;20: 1567-1571.